Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07309757

Maternal Outcomes With Methamphetamine Use and Cardiac Assessment for Rural Dissemination (MOM CARD)

The purpose of this study is to develop a pilot screening protocol, comparing cardiac point-of-care ultrasound (POCUS), electrocardiogram (EKG), serum biomarkers (N-terminal pro b-type natriuretic peptide (NT-proBNP), high sensitivity troponin (hsTn)) with formal transthoracic echocardiogram (TTE) in pregnant women with methamphetamine use.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year–65 year

Sex eligibility

Female

Study type

Observational

About this study

This is a pilot study that examines previously undiagnosed cardiac pathology utilizing transthoracic echocardiogram (TTE) in pregnant women with chronic methamphetamine use and assesses possible screening modalities (cardiac point-of-care ultrasound (POCUS), serum biomarkers, electrocardiogram (EKG)) in identifying underlying disease in this population. As this is a prospective observational study, we will assess pregnancy-related complications and care connections in the pilot tertiary academic setting.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 18 years or older > 20 weeks gestation admitted to the hospital
  • Active patient-defined regular methamphetamine use for at least 1 year and any use within the last month
  • Able to understand and provide informed consent
  • Able to understand English

Exclusion criteria

These criteria will exclude women whose medications, personal traits, obstetric conditions, or diseases could confound cardiovascular risk.

  • Prescribed stimulants
  • Echocardiogram or EKG previously performed during current pregnancy
  • Previous diagnosis of congestive heart dysfunction
  • Previous diagnosis of pulmonary hypertension
  • Previous myocardial infarction
  • Previous diagnosis of endocarditis
  • Prior cardiac intervention (repair of cardiac congenital lesion, valve replacement or repairs, percutaneous/operative treatment of arrhythmias)
  • High-risk aortopathy (Marfan syndrome, bicuspid aortopathy, prior aortic dissection)

Treatment and study plan

Primary outcomes

  1. Sensitivity of point of care cardiac ultrasound for the detection of left ventricular systolic dysfunction as compared to comprehensive transthoracic echocardiogram.

    Time frame: Day 1

    This outcome seeks to identify the sensitivity of point of care cardiac ultrasound for the identification of left ventricular systolic dysfunction in pregnant people who use methamphetamine when performed by an obstetrics provider, as compared to formal transthoracic echocardiogram.

Secondary outcomes

  1. Sensitivity of cardiac biomarkers and ECG for the identification of left ventricular systolic dysfunction as compared to comprehensive transthoracic echocardiogram. methamphetamine

    Time frame: Day 1

    This outcome seeks to identify the sensitivity of N-terminal pro-B-type natriuretic peptide (NT-proBNP), high sensitivity troponin and electrocardiogram for the identification of left ventricular systolic dysfunction in pregnant people who use methamphetamine, as compared to formal transthoracic echocardiogram.

  2. Prevalence of underlying structural heart disease in pregnant people who use methamphetamine

    Time frame: Day 1

    This outcome seeks to identify the prevalence of structural heart disease in pregnant people who use methamphetamine.

  3. Pregnancy and delivery outcomes in people who use methamphetamine

    Time frame: 3 months postpartum

    This outcome seeks to identify the prevalence of pregnancy delivery complications in people who use methamphetamine.

  4. Changes to pregnancy-related treatment plan based on cardiovascular screening in people who use methamphetamine.

    Time frame: 3 months postpartum

    This outcome seeks to identify linkage to cardiovascular and addiction specialty care among patients diagnosed with cardiovascular disease.

Study contacts

Contact information is provided by the study sponsor or research team.

Evan Shalen, MD

CONTACT

[email protected]

503-494-1775

Sara McCrimmon

CONTACT

[email protected]

Sponsors and collaborators

Lead sponsor

Oregon Health and Science University

Other

Registry information

Important dates

Study start
2026
Primary completion
2026
Study completion
2027
First posted
Dec 30, 2025
Registry last updated
Jan 2, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.